- Home
- ORLA vs TERN Comparison
ORLA vs TERN Comparison
Compare ORLA & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORLA | TERN |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ORLA | TERN |
|---|---|---|
| Price | $14.57 | $36.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $27.00 | ★ $48.60 |
| AVG Volume (30 Days) | ★ 2.9M | 2.5M |
| Earning Date | 11-11-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 2239.45 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $772,153,000.00 | N/A |
| Revenue This Year | $183.80 | N/A |
| Revenue Next Year | $36.88 | N/A |
| P/E Ratio | $92.84 | ★ N/A |
| Revenue Growth | ★ 145.83 | N/A |
| 52 Week Low | $5.52 | $1.87 |
| 52 Week High | $15.54 | $48.26 |
Technical Indicators
Market Signals| Indicator | ORLA | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 50.65 |
| Support Level | $13.49 | $33.43 |
| Resistance Level | $15.54 | $38.37 |
| Average True Range (ATR) | 0.64 | 2.30 |
| MACD | 0.00 | -0.96 |
| Stochastic Oscillator | 64.84 | 42.26 |
Price Performance
Historical ComparisonAbout ORLA Orla Mining Ltd.
Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.